

October 1<sup>st</sup> 2008**Securities and Exchange Commission  
Office of International Corporate  
Finance**100 F Street, N.E., Mail Stop 3628  
Washington DC 20549  
USA**Rule 12g3-2(b) Exemption  
File No. 082-34965****PROCESSED**

OCT 15 2008

**THOMSON REUTERS SUPPL**

Dear Sir or Madam,

Enclosed is information ARKEMA :

- made or is required to make public under French law;
- filed or is required to file with and which is made public by Euronext Paris; or
- distributed or is required to distribute to its shareholders.

This information is being furnished under Paragraph (b)(1)(i) of Rule 12g3-2 of the Securities Exchange Act of 1934, as amended (*the Exchange Act*), with the understanding that such information and documents will not be deemed "filed" with the U.S. Securities and Exchange Commission or otherwise subject to the liabilities of Section 18 of the Exchange Act, and that neither this letter or the furnishing of such documents and information shall constitute an admission for any purpose that ARKEMA is subject to the Exchange Act.

Yours sincerely,


Vice President Investor Relations

Frédéric GAUVARD



ARKEMA  
4-8, cours Michelet  
92091 Paris La Défense  
Tél. : +33 (01 49 00 80 80 Fax : +33 (01 49 00 83 96

Siège social : ARKEMA - 4-8, cours Michelet - 92800 Puteaux (France)  
Société anonyme au capital de 520 868 634 euros  
445 074 685 RCS Nanterre - TVA Fr 32 319 632 790

[www.arkemagroup.com](http://www.arkemagroup.com)

**Enclosed documents**

- Press release : “ Arkema consolidates its Hydrazine Hydrate and Derivates activity at its Lannemezan industrial facility“

END